Clinical Trial ID: NCT03682536
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alpha for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Due to Myelodysplastic Syndrome (MDS) ESA-naive Participants who are Non-Transfusion Dependent (NTD): The ELEMENT-MDS Trial
Status
Open
Conditions
Other
Phases
III
Age Group
Adult
Main Investiagtor
Norkin, Maxim
Practice
Bone Marrow
Scope
National
Participating Institutions
Baptist MD Anderson Cancer Center
Nct ID Number
NCT03682536
Secondary Trial ID Number
CA 056-025 / ELEMENT-MDS
Keywords
Treatment